HRTX - Heron Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
23.78
-0.86 (-3.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.64
Open24.52
Bid23.55 x 800
Ask25.65 x 2200
Day's Range23.74 - 24.87
52 Week Range21.25 - 42.90
Volume1,088,474
Avg. Volume880,240
Market Cap1.859B
Beta (3Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-2.44
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.90
Trade prices are not sourced from all markets
  • PR Newswire13 days ago

    77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy

    - Bunionectomy Results Complement Opioid-Free Results from the Previously Reported Hernia Repair Study - SAN DIEGO , March 11, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage ...

  • GlobeNewswire19 days ago

    Report: Exploring Fundamental Drivers Behind Caesars Entertainment, Party City Holdco, Rowan Companies, TiVo, Heron Therapeutics, and Cimarex Energy — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire19 days ago

    Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

    SAN DIEGO, March 4, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Monday, March 11, 2019, at 2:10 p.m. EST at The Boston Marriott Copley Place. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs.

  • PR Newswire25 days ago

    Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push

    SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion, for intravenous (IV) use. CINVANTI is the first and only polysorbate 80-free, IV formulation of an NK1 receptor antagonist (RA) indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND® capsules.

  • Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
    Zackslast month

    Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates

    Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -36.96% and 2.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Heron Therapeutics: 4Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 63 cents. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...

  • PR Newswirelast month

    Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress

    SAN DIEGO , Feb. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • PR Newswirelast month

    Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference

    SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019, at 1:00 p.m. EST at the Lotte New York Palace Hotel. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs.

  • How Much Did Heron Therapeutics, Inc.’s (NASDAQ:HRTX) CEO Pocket Last Year?
    Simply Wall St.last month

    How Much Did Heron Therapeutics, Inc.’s (NASDAQ:HRTX) CEO Pocket Last Year?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Barry Quart became the CEO of Heron Read More...

  • PR Newswire2 months ago

    Heron Therapeutics Announces Retirement of Robert Rosen as President

    -Barry Quart, Pharm.D., Chief Executive Officer of Heron, to take on additional role of President- SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Mylan and Heron Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

    - Acceptance of HTX-011 NDA for Postoperative Pain Management with Priority Review Designation; PDUFA Date of April 30, 2019 - - 90% of Patients Treated with HTX-011 Opioid-Free 72 Hours Post-Surgery in ...

  • PR Newswire3 months ago

    90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study

    SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 63 patients undergoing hernia repair surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in hernia repair completed in 2018, this study included many of the same investigators and the same entry criteria as the Phase 3 study. The goal of the current study was to increase the proportion of opioid-free patients by combining HTX-011 with a regimen of readily available, oral analgesics.

  • Company News For Jan 2, 2019
    Zacks3 months ago

    Company News For Jan 2, 2019

    Companies In The News Are: BA,TXT,HRTX,GOOS,CWH

  • Heron Gains on Priority Review Designation for Pain Drug
    Zacks3 months ago

    Heron Gains on Priority Review Designation for Pain Drug

    Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

  • PR Newswire3 months ago

    Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    SAN DIEGO , Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • MarketWatch3 months ago

    Heron stock up 4.3% after opioid alternative granted priority review designation from FDA

    Shares of Heron Therapeutics rose 4.5% in premarket trade Monday after the company announced the U.S. Food and Drug Administration had accepted the new drug application for its non-opioid alternative for post-operative pain management, granting it priority review designation. The product, dubbed HTX-011, is a combination of a long-acting, extended-release form of local anesthetic bupivacaine and the anti-inflammatory medication meloxicam. "We believe that HTX-011 could have a considerable impact on the lives of patients by significantly reducing the proportion of patients who experience severe pain and receive opioids after surgery, especially at discharge," said Heron Chief Executive Barry D. Quart in a statement. The FDA had previously granted breakthrough therapy status for HTX-011 based on the results of Phase 2 studies and two completed Phase 3 studies. Those studies showed the drug produced significant reductions in pain intensity and need for opioids compared to a placebo and bupivacaine alone. Shares of Heron have gained 31% this year, while shares of the iShares NASDAQ Biotechnology ETF have fallen 11%. The S&P 500 has fallen 7%.

  • PR Newswire3 months ago

    FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management

    SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation. HTX-011 is a long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain.

  • Hedge Funds Are Buying Heron Therapeutics Inc (HRTX)
    Insider Monkey3 months ago

    Hedge Funds Are Buying Heron Therapeutics Inc (HRTX)

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Wall Street closed up on Wednesday as dovish comments made by Federal Reserve Chairman Jerome Powell boosted investor optimism. According to the Chairman, Jerome Powell, “Interest rates are still low by historical standards, and they remain just below the broad range of estimates of the level that would be neutral for the economy — that is, neither speeding up nor slowing down growth.” The Dow Jones Industrial Average surged 2.5 percent to close at 25,366.43, while the S&P 500 Index jumped 2.3 percent to close at 2,743.79. “Markets wanted to hear Powell say that there is no preset course of rates, that he is mindful of weaknesses in the global economy, and, most importantly, that tariffs have altered the calculus of the future of the U.S. economy,” Cox said.

  • GlobeNewswire4 months ago

    Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Cronos Group and Heron Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 26, 2018 / U.S. equities lost footing on Friday amidst drop in oil prices and selloff in FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet) stocks. ...

  • When Will Heron Therapeutics Inc (NASDAQ:HRTX) Become Profitable?
    Simply Wall St.4 months ago

    When Will Heron Therapeutics Inc (NASDAQ:HRTX) Become Profitable?

    Heron Therapeutics Inc’s (NASDAQ:HRTX): Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The US$2.1b market-cap company’s loss lessens since it announced a -US$197.5m Read More...

  • PR Newswire4 months ago

    Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

    SAN DIEGO , Nov. 20, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...